Righolt CH, Zhang G, Ye X, et al. - Researchers focused on the impact of chemical or pharmacodynamic properties of statins on their link with the risk of chronic lymphocytic leukemia (CLL) in this nested case–control study, given an attenuated risk among statin users has been reported in recent studies. Participants included all Manitobans (n = 1,385) ages ≥ 40 years, who were matched (on gender, age, residence, and duration of insurance coverage) to 6,841 cancer-free controls when they received a diagnosis of CLL (as a first cancer). By individual statins and groups ie, hydrophilic, low-potency lipophilic (fluvastatin and lovastatin), and high-potency lipophilic statins, they analyzed statin use by means of conditional logistic regression. A reduced CLL risk was reported in relation to low-potency lipophilic statin use, with a possible dose–response impact.